Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05211336
Title Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

central nervous system lymphoma

chronic lymphocytic leukemia

B-cell lymphoma

marginal zone B-cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

mantle cell lymphoma

Therapies

Lenalidomide + Nivolumab

Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.